Familial Mediterranean fever is an autoinflammatory disorder characterized by recurrent episodes of fever and serositis, which lead to pain in the abdomen, chest, joints, and muscles. Recognized subtypes have been described, with clinical presentations differing among affected individuals. Mutations in the MEFV gene, a regulator of innate immunity, are definitively associated with this condition. The disorder affects approximately 1 to 5 in 10,000 births, and the age of onset varies among patients. These facts are documented in the knowledge packet as of September 2026, providing a clear, packet-certified reference for this condition.

The clinical features of familial Mediterranean fever include recurrent episodes of fever accompanied by abdominal pain, arthralgia, myalgia, and constipation, all noted as very frequent symptoms in up to 90% of cases. In addition, patients often experience nausea and vomiting along with other manifestations such as erysipelas, seizures, diarrhea, and chest pain, which are reported frequently. Other symptoms seen in a moderate number of cases include arthritis, increased total leukocyte count, and sleep disturbance. This range of symptoms, documented with frequency annotations, reflects the variable and multi-system nature of the condition as captured in the packet.

Familial Mediterranean fever is caused by mutations in the MEFV gene, which encodes a protein involved in the regulation of the innate immune response. The association between MEFV abnormalities and the condition is classified as definitive by ClinGen, underscoring a clear genetic basis. Although the packet does not specify an inheritance pattern, the genetic link is strong and central to the disorder’s etiology. The gene’s role in inflammatory processes further explains the episodic fever and serosal inflammation seen in patients. This genetic basis is supported by the curated data provided in the knowledge packet.

Diagnosis of familial Mediterranean fever relies on clinical evaluation and the recognition of characteristic symptom patterns, as outlined in the packet. The condition is suspected in patients experiencing recurrent febrile episodes alongside serositis, including peritonitis, synovitis, and pleuritis, with supportive findings such as erysipelas-like erythema. Although specific laboratory diagnostic methods are not detailed in the packet, clinical guidelines indicate that thorough physical examinations and laboratory evaluations, including urinalysis when proteinuria is suspected, are integral in the diagnostic process. These diagnostic insights are based on expert review from GeneReviews within the packet.

Treatment of familial Mediterranean fever is guided by the availability of FDA-approved options documented in the packet. The current therapeutic approach includes the use of colchicine, with brands such as GLOPERBA, MITIGARE, and COLCRYS, as well as canakinumab (ILARIS), which are approved for use in this condition. These treatments are used to manage inflammatory episodes and reduce complications, such as amyloidosis, which can occur with untreated disease. The packet does not list specific foundational therapies beyond these approved treatments, and management recommendations follow established protocols as indicated by expert review in the GeneReviews section.

The long-term outlook for individuals with familial Mediterranean fever can vary, with the potential for severe complications if the condition is not managed appropriately. In particular, untreated patients, especially those with FMF type 1, are at risk of developing amyloidosis, which may lead to kidney failure. However, with timely and effective treatment, such as the use of FDA-approved agents, the progression of complications may be reduced. The packet does not provide a detailed natural history, and therefore, prognosis remains a variable aspect of the condition that depends on individualized management and treatment adherence as reflected in expert clinical guidelines.

Numerous certified active clinical trial records are present for familial Mediterranean fever, indicating ongoing research into various aspects of the disease. These studies are aimed at better understanding the condition’s mechanisms, evaluating potential novel therapies, and optimizing current management approaches. Active clinical trials for this condition are listed on ClinicalTrials.gov, providing a resource for up-to-date research information. Although the packet does not include detailed clinical trial descriptions, the presence of multiple active trial records underscores the interest in advancing knowledge and treatment options for individuals affected by this disorder.